Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its senior management will participate in a fireside chat at the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020, at 11:25 a.m. ET. Interested parties can access the live audio webcast through the 'News/Events' section on Aurinia's corporate website. A replay will also be available. Aurinia Pharmaceuticals is focused on developing therapies for serious diseases with high unmet medical needs, currently seeking FDA approval for voclosporin to treat lupus nephritis.
- None.
- None.
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET.
In order to participate in the audio webcast, interested parties can register and access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of LN. The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.
